The BIOMAP project has successfully concluded.

Read this article to learn more about the impact of BIOMAP and view our results in the publication section.

Stay tuned for more results to come. We will continue to update the publication section and inform you via our LinkedIn account when new results are published.

The BIOMAP Project Concludes with Pioneering Results and Resources

After six years of collaborative research, the BIOMAP project has successfully concluded, delivering significant progress in the understanding of atopic dermatitis and psoriasis. Through its integrative, large-scale approach, BIOMAP has generated foundational insights into disease mechanisms, classification, and management.

BIOMAP Results

BIOMAP’s integrative approach has delivered foundational insights into the pathobiology of atopic dermatitis and psoriasis. By identifying stable and dynamic disease endotypes and providing candidate biomarkers, the project is paving the way toward proactive, stratified care models.

The infrastructure developed, such as the data platform and security model, glossary for harmonisation, analytic tools, and resources generated, such as harmonised datasets, biomarker findings, and model systems, are set to inform future research and innovation in precision medicine. These developments carry potential socio-economic benefits through improved disease classification, risk prediction, treatment selection, and drug development.

A number of these results are in the process of being matopic dermatitise available as part of a sustainability effort to foster further collaborations and progress.

Overview of BIOMAP Results

  • A robust European Clinical Research Network was built and supported extensive data/sample sharing.
  • A pan-European virtual biobank and Data Portal were established and sustained, hosting harmonised clinical and omics data across cohorts. A robust and secure data management plan, along with detailed guidelines and a governance framework, has been set in place for upload, storage, and access of data, supported by legal documentation to ensure compliance with GDPR. This model has served as a blueprint for other IHI projects. The Data Portal is also subject to a sustainability effort based on the Consortium Agreement and GDPR requirements.
  • A “Glossary” for harmonisation of clinical data from diverse cohorts was established and published open access (DOI: 10.5281/zenodo.4746584). The vast majority of BIOMAP datasets have been harmonised using this glossary. A framework for standardisation of atopic dermatitis and psoriasis severity outcomes was also developed (DOI: 10.1093/bjd/ljae080). Consented pipelines for molecular data processing were established.
  • Genetic studies identified novel loci and genetic mechanisms contributing to disease severity, progression, and comorbidities, pinpointing potential therapeutic targets (DOIs: 10.1038/s41467-025-56719-8; 10.1001/jamacardio.2024.2859).
  • Omics analyses revealed candidate disease subtypes/endotypes, associated molecular signatures, and biomarkers (DOIs: 10.1038/s41467-023-41180-2; 10.1101/2023.10.04.23296543; 10.1038/s41588-023-01545-1; 10.1186/s12967-024-04879-4).
  • Analyses on population-based cohorts, disease registries and clinical studies identified key host and environmental factors modulating the skin microbiome and characterised the disease dysbiosis as well as differential impacts of established treatments (DOIs: 10.1111/all.15742; 10.1038/s41467-022-33906-5; 10.1016/j.jdermsci.2022.04.007; 10.1111/bjd.20072; 10.1093/bjd/ljae471).
  • Clinical disease trajectories were identified. Initial findings on atopic dermatitis subtypes based on trajectory, severity, and multimorbidity clusters have been published (DOIs: 10.1038/s41598-022-26357-x; 10.1111/bjd.19885).
  • First atopic dermatitis and psoriasis candidate endotypes and associated molecular signatures were identified and published (DOIs: 10.1016/j.jaci.2022.02.001; 10.1016/j.jaci.2020.06.012; 10.1016/j.jid.2023.02.010). These findings were extensively verified through federated analysis with industry partners and are currently being written up for further publications.
  • Spatial and flow cytometry analyses delivered insights into immune cell networks and their roles in disease endotypes (DOIs: 10.1038/s41467-024-44994-w; 10.1016/j.jaci.2022.04.027).
  • CRISPR/Cas9-based tools for generating in vitro model systems for multiomics analyses have been developed and made accessible to BIOMAP partners (DOI: 10.1016/j.jid.2023.02.021).
  • Multiple publications and tools were released, providing valuable publicly accessible resources for the research community.

Stay tuned for more results to come.
We will continue to update the publication section and inform you via our LinkedIn account when new results are published. Find further information on BIOMAP results on the CORDIS website.